Dharmendra Verma, MD
Gastroenterology · Katy, TXNPI 1225142623
Payments from drug & device makers
Across 404 payments — averaging $1549.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$404K
- Pfizer$42K
- Ipsen Bioscience Inc.$40K
- Teva Pharmaceuticals USA, Inc.$36K
- Janssen Research & Development, LLC$32K
- Eli Lilly$25K
- plus $47K from 31 others
Across 18 payments — averaging $2303.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$40K
- Sanofi US Services Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 177 | $404,004 |
| Pfizer(2 entities) | 85 | $41,689 |
| Ipsen Bioscience Inc. | 23 | $39,666 |
| Teva Pharmaceuticals USA, Inc. | 10 | $35,969 |
| Janssen Research & Development, LLC | 5 | $32,382 |
| Eli Lilly | 3 | $25,341 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $13,764 |
| Sanofi US Services Inc. | 3 | $12,005 |
| Intercept Pharmaceuticals, Inc. | 2 | $10,300 |
| Ipsen Pharma SAS | 4 | $8,015 |
| Johnson & Johnson | 6 | $244 |
| Madrigal Pharmaceuticals | 3 | $224 |
| Redhill Biopharma Inc. | 10 | $219 |
| Medtronic | 2 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $187 |
| Janssen Scientific Affairs, LLC | 2 | $185 |
| Conmed Corporation | 1 | $156 |
| Echosens North America, Inc. | 2 | $104 |
| Bristol Myers Squibb | 5 | $94 |
| Gilead | 1 | $91 |
| Apollo Endosurgery US Inc | 1 | $90 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Covidien LP | 2 | $87 |
| Ardelyx, Inc. | 3 | $74 |
| Novo Nordisk | 1 | $72 |
| Boehringer Ingelheim International GmbH | 2 | $69 |
| Evoke Pharma, Inc. | 3 | $67 |
| Lilly USA, LLC | 3 | $65 |
| Boston Scientific | 1 | $61 |
| Endogastric Solutions, Inc | 1 | $52 |
| Sanofi | 2 | $50 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Merit Medical Systems Inc | 1 | $49 |
| Celltrion USA Inc. | 2 | $43 |
| QOL Medical, LLC | 1 | $25 |
| Abbott | 1 | $23 |
| Capsovision, Inc. | 1 | $14 |
How this compares
$625,810 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Katy
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.